Topic Hub

Trials Empower Rt

5 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.

5articles

17keywords mapped

2026-05-25latest review

Explore

Trials Empower Rt library

Showing 5 of 5 clinical reviews.

Access2026-05-25

EMPEROR-Preserved Cost, Cost-Effectiveness, and Health-Economic Implications

Health-economic analyses of empagliflozin in HFpEF from the EMPEROR-Preserved trial: cost per QALY, payer coverage, list vs net pricing, and individual value calculations.

Read clinical review

Questions2026-05-25

EMPEROR-Preserved Extension Data and What Happened After the Trial Ended

Long-term follow-up from the EMPEROR-Preserved trial reveals durable empagliflozin benefits in HFpEF, emerging safety patterns, and unanswered questions about SGLT2 inhibitor therapy beyond the original 26-month median observation.

Read clinical review

Clinical Reviews2026-05-25

EMPEROR-Preserved Subgroup Analyses: Who Responded Most and Least

A detailed breakdown of pre-specified and post-hoc subgroup analyses from the EMPEROR-Preserved trial of empagliflozin in HFpEF, examining which patient populations saw the greatest and smallest benefit.

Read clinical review

Questions2026-05-25

EMPEROR-Preserved Trial: A Plain-English Overview of What It Established

Plain-English breakdown of the EMPEROR-Preserved trial showing empagliflozin reduced CV death and heart failure hospitalization by 21% in patients with HFpEF.

Read clinical review

Questions2026-05-25

What EMPOWER Actually Changes in Clinical Practice

Deep-dive into the EMPEROR-Preserved trial: how empagliflozin's 21% reduction in CV death or HF hospitalization reshaped guideline recommendations and prescribing for HFpEF patients.

Read clinical review